Αποτελέσματα Αναζήτησης
Although patients with heart failure with preserved ejection fraction (HFpEF) comprise nearly half of those with heart failure (HF), evidence-based treatment options have historically been limited. 1 Treatment guidelines have accordingly emphasized symptomatic management through relief of congestion and treatment of comorbidities. 2, 3 However ...
25 Ιουν 2024 · Multiple guidelines exist for the diagnosis and management of heart failure with preserved ejection fraction (HFpEF). We systematically reviewed current guidelines and recommendations, developed by national and international medical organizations, on the management of HFpEF in adults to aid clinical decision-making.
Despite the high prevalence of heart failure with preserved ejection fraction (HFpEF), our understanding of this disease is limited and it still carries significant morbidity and mortality worldwide. At present, physicians are burdened by the inconclusive benefits of currently available treatment options.
10 Νοε 2016 · Treatment of heart failure with a preserved ejection fraction should include diuretics for volume overload, treatment for cardiovascular and noncardiovascular coexisting conditions,...
Hypertension is the leading cause of HFpEF, with a prevalence ranging from 60% to 89%, 4 and BP control is well established for preventing HF. Effective treatment leads to regression of LVH, with ARB, ACEi and calcium channel blockers, causing more effective LVH regression than beta blockers or diuretics.
3 Σεπ 2024 · Summary. In this review, a clinical update is provided reviewing the most recent clinical trials and data regarding epidemiology, pathophysiology, diagnosis, and treatment of heart failure with preserved ejection fraction with an emphasis on the recent trend in cardiometabolic interventions. Similar content being viewed by others.
22 Μαρ 2024 · The ongoing SPIRIT-HF (Spironolactone in the Treatment of Heart Failure; NCT04727073) and SPIRRIT (Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction; NCT02901184) trials will shed more light on the role of spironolactone in HFpEF.
